| Mar 5, 2026 | NexCure | $19.0M Series A | RA Capital Management | Cencora Ventures, Oncology Ventures |
| Feb 10, 2026 | ILiAD Biotechnologies | $115.0M Series B | RA Capital Management | AI Life Sciences, BNP Capital, Janus Henderson Investors |
| Feb 5, 2026 | Angitia Biopharmaceuticals | $130.0M Series D | Frazier Life Sciences, Venrock | 3H Health Investment, Ascenta Capital, Bain Capital Life Sciences, BlackRock, BVF Partners, Elikon Venture, Hillhouse Capital Group, Janus Henderson Investors, Legend Capital, Logos Capital, Morningside, OrbiMed, TF Capital, Yonghua Capital |
| Oct 1, 2024 | Be Biopharma | $82.0M Series U | — | ARCH Venture Partners, Atlas Venture, Biomatics Capital Partners, Leaps by Bayer, Lux Capital, The Column Group, Isaac Ciechanover, Alta Partners, Bristol Myers Squibb, Longwood Fund, Takeda Ventures |
| May 1, 2024 | Vaxess Technologies | $12.0M Series U | — | The Engine, Vsquared Ventures, Engine Ventures, Global Health Investment Corporation, Mission BioCapital |
| Sep 1, 2023 | Vaxess Technologies | $9.0M Series U | — | The Engine, Ulu Ventures, Vsquared Ventures, Global Health Investment Corporation |
| Apr 1, 2023 | Cortica | $75.0M Series D | Deerfield Management, Optum Ventures | Asset Management Ventures, Fifth Wall, Franklin Templeton Investments, King River Capital, PS Investments, Y Combinator, Alex Tang, .406 Ventures, Ajax Health, Aperture Venture Partners, Autism Impact Fund, Echo Health Ventures, Longitude Capital, Questa Capital |
| Jun 1, 2015 | Clementia Pharmaceuticals | $60.0M Series U | New Enterprise Associates | Amplitude VC, Mott Family Capital, OrbiMed, Soffinova Partners, BDC Capital, EcoR1 Capital, Janus Henderson Investors, Rock Springs Capital, UCB Ventures |
